ZLAB Zai Lab Limited Forecast, Technical & Fundamental Analysis
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases... Show more
ZLAB is expected to report earnings to rise 1,107.80% to -60 cents per share on August 10
Q2'26
Est.
$-0.60
Q1'26
Beat
by $0.42
Q4'25
Beat
by $0.32
Q3'25
Missed
by $0.08
Q2'25
Beat
by $0.37
The last earnings report on May 07 showed earnings per share of -5 cents, beating the estimate of -46 cents. With 506.38K shares outstanding, the current market capitalization sits at 2.29B.
A.I.dvisor indicates that over the last year, ZLAB has been loosely correlated with ONC. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ZLAB jumps, then ONC could also see price increases.
Aroon Indicator for ZLAB shows an upward move is likely
ZLAB's Aroon Indicator triggered a bullish signal on July 13, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 149 similar instances where the Aroon Indicator showed a similar pattern. In of the 149 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 15, 2026. You may want to consider a long position or call options on ZLAB as a result. In of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ZLAB just turned positive on June 11, 2026. Looking at past instances where ZLAB's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .
ZLAB moved above its 50-day moving average on July 02, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ZLAB crossed bullishly above the 50-day moving average on July 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ZLAB advanced for three days, in of 256 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for ZLAB moved out of overbought territory on July 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
ZLAB broke above its upper Bollinger Band on July 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.347) is normal, around the industry mean (22.746). P/E Ratio (0.000) is within average values for comparable stocks, (37.261). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.488). ZLAB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (4.769) is also within normal values, averaging (432.117).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ZLAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZLAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
